Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Feb 07, 2023 2:26pm
147 Views
Post# 35272468

RE:RE:RE:Personalized Medicine...

RE:RE:RE:Personalized Medicine...You guys should really take things up with the FA80 given their connections to the Board room.  Most of us only have connections to the Bored room.

Presumably they would be aware of any Mgt shortcomings,  and YET....

....they insist on coughing up the cash, whenever it's needed.

For $ 11M (less of course the new Baxter quasi-equity contribution) I would have reserved the right to at least submit a sternly worded letter once in a while.


50 down/40 to go (3b)*
or rather 220 down/40 to go* (see confirmatory and Euphrates 3a add-ins)
220/260 = 85% = 15 yard line (US rules ....NFL field)
Well within field goal range, but I think they want the major score.
Fumble possible, but unlikely IMO.
Using up all their time-outs for some reason

* assuming FDA likes Interim data given: exceeding expectations, breakthru status, combined stats, RWE, and open label nature of Trial.
<< Previous
Bullboard Posts
Next >>